Trastuzumab is a biopharmaceutical used to treat several types of breast cancer, gastric cancer, and salivary gland cancer. The drug is administered to patients via intravenous infusion and is marketed as trastuzumab powder that can be reconstituted into an injectable solution. Trastuzumab was first approved for medical use in 1998. As of now, the drug has become approved in and supplied to over 120 countries and is included in the World Health Organisation's list of Essential Medicines that contain the safest and most effective drugs recommended for a health system. The three branded drugs that account for the largest part of the global trastuzumab market share are Herceptin, Kadcyla, and Perjeta all marketed by manufacturer and supplier Roche. Of the three drugs, Herceptin and Perjeta are considerably cheaper, albeit less effective alternatives to Kadcyla. Other manufacturers and suppliers of trastuzumab medications include Pfizer, Celltrion, and Amgen. What is more, following Roche's patent expiry (in 2014 in Europe, and 2019 in the U.S.) many manufacturing companies began marketing biosimilar versions of the drug. Suppliers of biosimilars include Biocon, Mylan, Aryogen, and many more. Ogivri (trastuzumab-dust) was authorized by the FDA in December 2017 as a copycat to Herceptin (trastuzumab) again for people with locally advanced throat cancer (gastric or esophageal region carcinoma) whose tumors exasperates the HER2 gene (HER2+). As per the clinical evidence, it has biosimilar qualities to Herceptin. Although Ogivri is the first copycat licensed in the United States for the therapy of breast or throat cancer, it is the 2nd biosimilar approved for the therapy of cancer in the United States. Herzuma (trastuzumab-curb) is a biosimilar medicine authorized for the therapy of HER2-positive breast cancer in December 2018. One other biosimilar authorized by the FDA in June 2019 is KANJINTI (trastuzumab-anns).

Trastuzumab is a synthetic monoclonal antibody that targets the HER-2 channel, a photo-oncogene that belongs to the EGF receptor family. When abundantly expressed in breast cancer cells, HER-2 forms heterodimers, which overamplify the signal produced by the other HER group sensors. A transmembrane protein tyrosine receptor, the HER-2 receptor has an extracellular alkene domain, a hydrophobic region, and an internal or cytoplasmic protein tyrosine site. It is activated by the creation of heterodimers or heterodimers with the other EGFR molecules, which results in dimerization and phosphorylation and/or transphosphorylation of particular tyrosine residues in the internal regions of EGFR. Trastuzumab attaches to the extrinsic ligand-binding site of HER-2 and prevents its extracellular ligand from being cleaved, resulting in specific antibodies transmitter implement to generate and inhibition of HER-2-mediated internal signaling cascades. The MAPK and PI3K/Akt networks are inhibited, resulting in higher induction of apoptosis and suppression of cell growth. Trastuzumab also activates specific antibodies mitochondrial lethality by drawing immune cells, such as NK cells, to HER-2 overexpressed tumor locations. Trastuzumab attaches to the external ligand-binding area of HER-2 and prevents its extracellular ligand from being cleaved, resulting in antibody-induced receptors implement to generate and inhibition of HER-2-mediated internal signaling cascades. The MAPK and PI3K/Akt pathways are inhibited, increasing from cycle arrest and repression of cell growth and differentiation.

Trastuzumab and its biosimilar drugprices vary depending on the country of origin, costs incurred by manufacturing companies, supplier pricing, and similar factors. In the US, wholesale prices for a 150mg sachet of trastuzumab powder approximate to around $250. Trastuzumab is available for sale from a variety of Trastuzumab vendors at a range of costs. Prices are only valid for consumers who pay cash and do not apply to insurance coverage. Trastuzumab suppliers, on the whole, are in favor of patient aid initiatives. Varying drugstores may have different prices.

Being a global B2B pharmaceutical online marketplace, Pipelinepharma is structured to simplify pharmaceutical deals by providing you with an intuitive interface that is easy to engage with. The selection of Trastuzumab offerings can be narrowed down with the use of filters and easily weighed against one another according to medication prices and commercial terms. The advanced filters help you filter out the countries for Trastuzumab manufacturers and Trastuzumab suppliers that you are looking for. These also enable you to check the dossier status of Trastuzumab, and the GMP approvals of the different variants of Trastuzumab. Also, each manufacturer or supplier product description contains essential information about Trastuzumab including clinical data, stability zones, countries where Trastuzumab is already registered in. Manufacturers also have special, and delivery terms.

If you are a pharmaceutical licensing company or a distributor you can enter into deals or negotiations over Trastuzumab offers with manufacturing companies after completing the free registration process and joining our online marketplace. This helps to ensure that you conclude the pharmaceutical deal at a reasonable cost and achieve the best cost/benefit ratio for your company while bypassing lengthy sourcing, negotiation, and order process. Once you have finalized a deal, you can look forward to a long-lasting business relationship with the manufacturers or suppliers. This way, the marketplace allows you as a distributor to skip the process of making a list of product manufacturers every time you are looking for in-licensing or distribution deals.

To keep up to the quality standards other than the Good Manufacturing Practice approvals that Trastuzumab manufacturers list has, we qualify their companies before they are boarded on the platform. This allows us to screen Trastuzumab manufacturers for the quality of the pharmaceutical products’ dossiers and protect against the risk of possible malpractices.